カテゴリー： 世界, 医療/バイオ, LP Information

世界の吸入用組換え新型コロナウイルスワクチン市場予測 2023年-2029年

【英語タイトル】Global Recombinant Novel Coronavirus Vaccine for Inhalation Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC10029）・商品コード：LP23DC10029
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：78
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の吸入用組換え新型コロナウイルスワクチン市場」は、過去の販売実績から2022年の世界の吸入用組換え新型コロナウイルスワクチンの総販売量を検討し、2023年から2029年の予測される吸入用組換え新型コロナウイルスワクチンの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の吸入用組換え新型コロナウイルスワクチンの市場規模を掲載し、XXX百万米ドル規模の世界の吸入用組換え新型コロナウイルスワクチン市場の詳細な分析を提供します。本インサイトレポートは、世界の吸入用組換え新型コロナウイルスワクチン業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の吸入用組換え新型コロナウイルスワクチン市場における各社の独自のポジションをより深く理解するために、吸入用組換え新型コロナウイルスワクチン製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の吸入用組換え新型コロナウイルスワクチン市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。吸入用組換え新型コロナウイルスワクチンの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。吸入用組換え新型コロナウイルスワクチンの中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。吸入用組換え新型コロナウイルスワクチンのヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

吸入用組換え新型コロナウイルスワクチンの世界主要メーカーとしては、CanSino Bio、 Aerogenなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の吸入用組換え新型コロナウイルスワクチン市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では吸入用組換え新型コロナウイルスワクチン市場をセグメンテーションし、種類別 (18～35歳、35～50歳、>50歳)、用途別 (病院、外来センター、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：18～35歳、35～50歳、>50歳

・用途別区分：病院、外来センター、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の吸入用組換え新型コロナウイルスワクチン市場の10年間の市場状況・展望は？
・世界および地域別に見た吸入用組換え新型コロナウイルスワクチン市場成長の要因は何か？
・吸入用組換え新型コロナウイルスワクチンの市場機会はエンドマーケットの規模によってどのように変化するのか？
・吸入用組換え新型コロナウイルスワクチンのタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：吸入用組換え新型コロナウイルスワクチンの年間販売量2018-2029、地域別現状・将来分析
・吸入用組換え新型コロナウイルスワクチンの種類別セグメント：18～35歳、35～50歳、>50歳
・吸入用組換え新型コロナウイルスワクチンの種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・吸入用組換え新型コロナウイルスワクチンの用途別セグメント：病院、外来センター、その他
・吸入用組換え新型コロナウイルスワクチンの用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の吸入用組換え新型コロナウイルスワクチン市場
・企業別のグローバル吸入用組換え新型コロナウイルスワクチン市場データ：2018-2023年の年間販売量、市場シェア
・企業別の吸入用組換え新型コロナウイルスワクチンの年間売上：2018-2023年の売上、市場シェア
・企業別の吸入用組換え新型コロナウイルスワクチン販売価格
・主要企業の吸入用組換え新型コロナウイルスワクチン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

吸入用組換え新型コロナウイルスワクチンの地域別レビュー
・地域別の吸入用組換え新型コロナウイルスワクチン市場規模2018-2023：年間販売量、売上
・主要国別の吸入用組換え新型コロナウイルスワクチン市場規模2018-2023：年間販売量、売上
・南北アメリカの吸入用組換え新型コロナウイルスワクチン販売の成長
・アジア太平洋の吸入用組換え新型コロナウイルスワクチン販売の成長
・ヨーロッパの吸入用組換え新型コロナウイルスワクチン販売の成長
・中東・アフリカの吸入用組換え新型コロナウイルスワクチン販売の成長

南北アメリカ市場
・南北アメリカの国別の吸入用組換え新型コロナウイルスワクチン販売量、売上（2018-2023）
・南北アメリカの吸入用組換え新型コロナウイルスワクチンの種類別販売量
・南北アメリカの吸入用組換え新型コロナウイルスワクチンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の吸入用組換え新型コロナウイルスワクチン販売量、売上（2018-2023）
・アジア太平洋の吸入用組換え新型コロナウイルスワクチンの種類別販売量
・アジア太平洋の吸入用組換え新型コロナウイルスワクチンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の吸入用組換え新型コロナウイルスワクチン販売量、売上（2018-2023）
・ヨーロッパの吸入用組換え新型コロナウイルスワクチンの種類別販売量
・ヨーロッパの吸入用組換え新型コロナウイルスワクチンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の吸入用組換え新型コロナウイルスワクチン販売量、売上（2018-2023）
・中東・アフリカの吸入用組換え新型コロナウイルスワクチンの種類別販売量
・中東・アフリカの吸入用組換え新型コロナウイルスワクチンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・吸入用組換え新型コロナウイルスワクチンの製造コスト構造分析
・吸入用組換え新型コロナウイルスワクチンの製造プロセス分析
・吸入用組換え新型コロナウイルスワクチンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・吸入用組換え新型コロナウイルスワクチンの主要なグローバル販売業者
・吸入用組換え新型コロナウイルスワクチンの主要なグローバル顧客

地域別の吸入用組換え新型コロナウイルスワクチン市場予測レビュー
・地域別の吸入用組換え新型コロナウイルスワクチン市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・吸入用組換え新型コロナウイルスワクチンの種類別市場規模予測
・吸入用組換え新型コロナウイルスワクチンの用途別市場規模予測

主要企業分析
CanSino Bio、 Aerogen
・企業情報
・吸入用組換え新型コロナウイルスワクチン製品
・吸入用組換え新型コロナウイルスワクチン販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Recombinant Novel Coronavirus Vaccine for Inhalation market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Recombinant Novel Coronavirus Vaccine for Inhalation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Recombinant Novel Coronavirus Vaccine for Inhalation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Recombinant Novel Coronavirus Vaccine for Inhalation is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Recombinant Novel Coronavirus Vaccine for Inhalation players cover CanSino Bio and Aerogen etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)’ newest research report, the “Recombinant Novel Coronavirus Vaccine for Inhalation Industry Forecast” looks at past sales and reviews total world Recombinant Novel Coronavirus Vaccine for Inhalation sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Novel Coronavirus Vaccine for Inhalation sales for 2023 through 2029. With Recombinant Novel Coronavirus Vaccine for Inhalation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Novel Coronavirus Vaccine for Inhalation industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Novel Coronavirus Vaccine for Inhalation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Novel Coronavirus Vaccine for Inhalation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Novel Coronavirus Vaccine for Inhalation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Novel Coronavirus Vaccine for Inhalation and breaks down the forecast by age, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Novel Coronavirus Vaccine for Inhalation.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Novel Coronavirus Vaccine for Inhalation market by product age, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by age
18-35 Years Old
35-50 Years Old
>50 Years Old
Segmentation by application
Hospital
Outpatient Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
CanSino Bio
Aerogen
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Novel Coronavirus Vaccine for Inhalation market?
What factors are driving Recombinant Novel Coronavirus Vaccine for Inhalation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Novel Coronavirus Vaccine for Inhalation market opportunities vary by end market size?
How does Recombinant Novel Coronavirus Vaccine for Inhalation break out age, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Recombinant Novel Coronavirus Vaccine for Inhalation by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Recombinant Novel Coronavirus Vaccine for Inhalation by Country/Region, 2018, 2022 & 2029
2.2 Recombinant Novel Coronavirus Vaccine for Inhalation Segment by Age
2.2.1 18-35 Years Old
2.2.2 35-50 Years Old
2.2.3 >50 Years Old
2.3 Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age
2.3.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Age (2018-2023)
2.3.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue and Market Share by Age (2018-2023)
2.3.3 Global Recombinant Novel Coronavirus Vaccine for Inhalation Sale Price by Age (2018-2023)
2.4 Recombinant Novel Coronavirus Vaccine for Inhalation Segment by Application
2.4.1 Hospital
2.4.2 Outpatient Center
2.4.3 Others
2.5 Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application
2.5.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Sale Market Share by Application (2018-2023)
2.5.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue and Market Share by Application (2018-2023)
2.5.3 Global Recombinant Novel Coronavirus Vaccine for Inhalation Sale Price by Application (2018-2023)
3 Global Recombinant Novel Coronavirus Vaccine for Inhalation by Company
3.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Breakdown Data by Company
3.1.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Sales by Company (2018-2023)
3.1.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Company (2018-2023)
3.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Revenue by Company (2018-2023)
3.2.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Company (2018-2023)
3.2.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Company (2018-2023)
3.3 Global Recombinant Novel Coronavirus Vaccine for Inhalation Sale Price by Company
3.4 Key Manufacturers Recombinant Novel Coronavirus Vaccine for Inhalation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Novel Coronavirus Vaccine for Inhalation Product Location Distribution
3.4.2 Players Recombinant Novel Coronavirus Vaccine for Inhalation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Recombinant Novel Coronavirus Vaccine for Inhalation by Geographic Region
4.1 World Historic Recombinant Novel Coronavirus Vaccine for Inhalation Market Size by Geographic Region (2018-2023)
4.1.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Recombinant Novel Coronavirus Vaccine for Inhalation Market Size by Country/Region (2018-2023)
4.2.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Sales by Country/Region (2018-2023)
4.2.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Revenue by Country/Region (2018-2023)
4.3 Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales Growth
4.4 APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales Growth
4.5 Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales Growth
4.6 Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales Growth
5 Americas
5.1 Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country
5.1.1 Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country (2018-2023)
5.1.2 Americas Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Country (2018-2023)
5.2 Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age
5.3 Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Region
6.1.1 APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Region (2018-2023)
6.1.2 APAC Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Region (2018-2023)
6.2 APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age
6.3 APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Novel Coronavirus Vaccine for Inhalation by Country
7.1.1 Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country (2018-2023)
7.1.2 Europe Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Country (2018-2023)
7.2 Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age
7.3 Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation by Country
8.1.1 Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country (2018-2023)
8.1.2 Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Country (2018-2023)
8.2 Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age
8.3 Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Novel Coronavirus Vaccine for Inhalation
10.3 Manufacturing Process Analysis of Recombinant Novel Coronavirus Vaccine for Inhalation
10.4 Industry Chain Structure of Recombinant Novel Coronavirus Vaccine for Inhalation
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Novel Coronavirus Vaccine for Inhalation Distributors
11.3 Recombinant Novel Coronavirus Vaccine for Inhalation Customer
12 World Forecast Review for Recombinant Novel Coronavirus Vaccine for Inhalation by Geographic Region
12.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Market Size Forecast by Region
12.1.1 Global Recombinant Novel Coronavirus Vaccine for Inhalation Forecast by Region (2024-2029)
12.1.2 Global Recombinant Novel Coronavirus Vaccine for Inhalation Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Novel Coronavirus Vaccine for Inhalation Forecast by Age
12.7 Global Recombinant Novel Coronavirus Vaccine for Inhalation Forecast by Application
13 Key Players Analysis
13.1 CanSino Bio
13.1.1 CanSino Bio Company Information
13.1.2 CanSino Bio Recombinant Novel Coronavirus Vaccine for Inhalation Product Portfolios and Specifications
13.1.3 CanSino Bio Recombinant Novel Coronavirus Vaccine for Inhalation Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 CanSino Bio Main Business Overview
13.1.5 CanSino Bio Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Recombinant Novel Coronavirus Vaccine for Inhalation Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Recombinant Novel Coronavirus Vaccine for Inhalation Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 18-35 Years Old
Table 4. Major Players of 35-50 Years Old
Table 5. Major Players of >50 Years Old
Table 6. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age (2018-2023) & (K Units)
Table 7. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Age (2018-2023)
Table 8. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Age (2018-2023) & ($ million)
Table 9. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Age (2018-2023)
Table 10. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sale Price by Age (2018-2023) & (US$/Unit)
Table 11. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application (2018-2023) & (K Units)
Table 12. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Application (2018-2023)
Table 13. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Application (2018-2023)
Table 14. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Application (2018-2023)
Table 15. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Company (2018-2023) & (K Units)
Table 17. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Company (2018-2023)
Table 18. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Company (2018-2023)
Table 20. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Recombinant Novel Coronavirus Vaccine for Inhalation Producing Area Distribution and Sales Area
Table 22. Players Recombinant Novel Coronavirus Vaccine for Inhalation Products Offered
Table 23. Recombinant Novel Coronavirus Vaccine for Inhalation Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share Geographic Region (2018-2023)
Table 28. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Country/Region (2018-2023)
Table 32. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country (2018-2023) & (K Units)
Table 35. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Country (2018-2023)
Table 36. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Country (2018-2023)
Table 38. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Type (2018-2023) & (K Units)
Table 39. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application (2018-2023) & (K Units)
Table 40. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Region (2018-2023) & (K Units)
Table 41. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Region (2018-2023)
Table 42. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Region (2018-2023)
Table 44. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age (2018-2023) & (K Units)
Table 45. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application (2018-2023) & (K Units)
Table 46. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country (2018-2023) & (K Units)
Table 47. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Country (2018-2023)
Table 48. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Country (2018-2023)
Table 50. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Type (2018-2023) & (K Units)
Table 51. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Age (2018-2023) & (K Units)
Table 57. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Recombinant Novel Coronavirus Vaccine for Inhalation
Table 59. Key Market Challenges & Risks of Recombinant Novel Coronavirus Vaccine for Inhalation
Table 60. Key Industry Trends of Recombinant Novel Coronavirus Vaccine for Inhalation
Table 61. Recombinant Novel Coronavirus Vaccine for Inhalation Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Recombinant Novel Coronavirus Vaccine for Inhalation Distributors List
Table 64. Recombinant Novel Coronavirus Vaccine for Inhalation Customer List
Table 65. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Forecast by Age (2024-2029) & (K Units)
Table 76. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Forecast by Age (2024-2029) & ($ Millions)
Table 77. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. CanSino Bio Basic Information, Recombinant Novel Coronavirus Vaccine for Inhalation Manufacturing Base, Sales Area and Its Competitors
Table 80. CanSino Bio Recombinant Novel Coronavirus Vaccine for Inhalation Product Portfolios and Specifications
Table 81. CanSino Bio Recombinant Novel Coronavirus Vaccine for Inhalation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. CanSino Bio Main Business
Table 83. CanSino Bio Latest Developments
Table 84. Aerogen Basic Information, Recombinant Novel Coronavirus Vaccine for Inhalation Manufacturing Base, Sales Area and Its Competitors
Table 85. Aerogen Recombinant Novel Coronavirus Vaccine for Inhalation Product Portfolios and Specifications
Table 86. Aerogen Recombinant Novel Coronavirus Vaccine for Inhalation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Aerogen Main Business
Table 88. Aerogen Latest Developments
List of Figures
Figure 1. Picture of Recombinant Novel Coronavirus Vaccine for Inhalation
Figure 2. Recombinant Novel Coronavirus Vaccine for Inhalation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Recombinant Novel Coronavirus Vaccine for Inhalation Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 18-35 Years Old
Figure 10. Product Picture of 35-50 Years Old
Figure 11. Product Picture of >50 Years Old
Figure 12. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Age in 2022
Figure 13. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Age (2018-2023)
Figure 14. Recombinant Novel Coronavirus Vaccine for Inhalation Consumed in Hospital
Figure 15. Global Recombinant Novel Coronavirus Vaccine for Inhalation Market: Hospital (2018-2023) & (K Units)
Figure 16. Recombinant Novel Coronavirus Vaccine for Inhalation Consumed in Outpatient Center
Figure 17. Global Recombinant Novel Coronavirus Vaccine for Inhalation Market: Outpatient Center (2018-2023) & (K Units)
Figure 18. Recombinant Novel Coronavirus Vaccine for Inhalation Consumed in Others
Figure 19. Global Recombinant Novel Coronavirus Vaccine for Inhalation Market: Others (2018-2023) & (K Units)
Figure 20. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Application (2022)
Figure 21. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Application in 2022
Figure 22. Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market by Company in 2022 (K Units)
Figure 23. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Company in 2022
Figure 24. Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Company in 2022
Figure 26. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales 2018-2023 (K Units)
Figure 29. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Revenue 2018-2023 ($ Millions)
Figure 30. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales 2018-2023 (K Units)
Figure 31. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Revenue 2018-2023 ($ Millions)
Figure 32. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales 2018-2023 (K Units)
Figure 33. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Revenue 2018-2023 ($ Millions)
Figure 36. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Country in 2022
Figure 37. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Country in 2022
Figure 38. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Age (2018-2023)
Figure 39. Americas Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Application (2018-2023)
Figure 40. United States Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Region in 2022
Figure 45. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Regions in 2022
Figure 46. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Age (2018-2023)
Figure 47. APAC Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Application (2018-2023)
Figure 48. China Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Country in 2022
Figure 56. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Country in 2022
Figure 57. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Age (2018-2023)
Figure 58. Europe Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Application (2018-2023)
Figure 59. Germany Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Age (2018-2023)
Figure 67. Middle East & Africa Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share by Application (2018-2023)
Figure 68. Egypt Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Recombinant Novel Coronavirus Vaccine for Inhalation in 2022
Figure 74. Manufacturing Process Analysis of Recombinant Novel Coronavirus Vaccine for Inhalation
Figure 75. Industry Chain Structure of Recombinant Novel Coronavirus Vaccine for Inhalation
Figure 76. Channels of Distribution
Figure 77. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Forecast by Region (2024-2029)
Figure 78. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share Forecast by Age (2024-2029)
Figure 80. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share Forecast by Age (2024-2029)
Figure 81. Global Recombinant Novel Coronavirus Vaccine for Inhalation Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Recombinant Novel Coronavirus Vaccine for Inhalation Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の吸入用組換え新型コロナウイルスワクチン市場予測 2023年-2029年] (コード：LP23DC10029)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の吸入用組換え新型コロナウイルスワクチン市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の動物吸入チャンバー市場予測 2023年-2029年
  • 世界のサルメテロール吸入液市場予測 2023年-2029年
  • 世界の組換えヒト血清アルブミン市場予測 2023年-2029年
  • 世界の呼吸器用吸入製品市場予測 2023年-2029年
  • 世界の組換えストレプトキナーゼ市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆